Addison’s Disease Treatment Market Size in 2022, Impact of COVID-19, Growth, Share, Applications, SWOT analysis, Forecast 2028

Addison’s disease, also known as primary adrenal insufficiency and hypocortisolism, is a long-term endocrine disorder in which the adrenal glands do not produce enough steroid hormones. Symptoms generally come on slowly and may include abdominal pain, weakness, and weight loss. Darkening of the skin in certain areas may also occur. Under certain circumstances, an adrenal crisis may occur with low blood pressure, vomiting, lower back pain, and loss of consciousness. An adrenal crisis can be triggered by stress, such as from an injury, surgery, or infection.Report OverviewDue to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Addison’s Disease Treatment estimated at USD 1213.6 million in the year 2022, is projected to reach a revised size of USD 1569.6 million by 2028, growing at a CAGR of 4.4% during the forecast period 2022-2028.The USA market for Addison’s Disease Treatment is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The China market for Addison’s Disease Treatment is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The Europe market for Addison’s Disease Treatment is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The global key companies of Addison’s Disease Treatment include Pfizer, GlaxoSmithKline, Takeda, Abbott Laboratories, Merck, Boehringer Ingelheim, Amgen and Lupin Pharmaceuticals, etc. In 2021, the global top five players had a share approximately percent in terms of revenue.